Dr. Gerald I. Hurowitz serves as President of Deontix Inc, a subsidiary of ILM Health and the centerpiece of ILM Health’s total mental health solution. A visionary physician-entrepreneur with more than four decades of experience at the intersection of psychiatry, psychopharmacology, and health technology, he brings to the role a rare combination of clinical depth, academic distinction, entrepreneurial achievement, and an unwavering commitment to health equity in mental health care.

A graduate of Yale University, Dr. Hurowitz earned his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University (Jefferson Medical College) in 1984, receiving the Baldwyn L. Kayes Prize in Psychiatry upon graduation. He completed his psychiatric residency at NYU/Bellevue and joined the faculty of Columbia University College of Physicians and Surgeons, where he has served as Assistant Professor of Clinical Psychiatry for more than 30 years. He also received an MA in Philosophy from the NYU Graduate School of Arts & Science. His clinical expertise is concentrated in psychopharmacology and neuropsychiatry, and he maintains an active practice in New York City. He is also a co-author of the chapter on Psychopharmacology and Electroconvulsive Therapy in the American Psychiatric Press Textbook of Psychiatry and has published widely in the fields of psychopharmacology and neuropsychiatry.

Dr. Hurowitz is perhaps best known in the health technology sector as a Co-Founder and Chief Medical Officer of M3 Information, where he helped develop and commercialize the M3 Checklist — the only clinically validated, multi-dimensional mental health screening tool proven to simultaneously assess risk for major depression, bipolar disorder, anxiety disorder, and PTSD in a single three-minute assessment. The M3 Checklist, validated through research published in the Annals of Family Medicine, was a breakthrough in addressing a long-standing gap in primary care: over 70% of mood disorder cases present first in non-psychiatric settings, yet existing tools screened for only one condition at a time. Dr. Hurowitz’s work at M3 helped reintegrate mental health into mainstream medicine, bringing measurement-based care to patients and clinicians at scale.

His perspective on technology is inseparable from his belief in health equity. Dr. Hurowitz has long recognized that mental health disparities fall disproportionately on underserved communities — those least likely to receive timely diagnosis, appropriate treatment, or access to specialist care. He sees technology not merely as a tool for efficiency, but as a vehicle for democratizing access to high-quality mental health care, ensuring that innovations reach every patient regardless of zip code, income, or insurance status. This conviction has guided his approach to building scalable, evidence-based platforms that can serve both the individual clinician and the broader population.

Dr. Hurowitz has presented at the American Psychiatric Association’s annual meeting, Columbia University’s Comprehensive Review of Current Neuropsychiatry, the New York State Psychiatric Institute’s Arden House Conference, and numerous other venues. He is recognized by peers as a uniquely versatile leader — a practicing clinician, rigorous academic, forward-thinking policy voice, and effective business builder — who brings credibility, strategic clarity, and deep mission alignment to every organization he leads.

At Deontix Inc, Dr. Hurowitz is positioned to translate decades of clinical insight and proven health technology innovation into a platform that transforms how mental health is detected, delivered, and experienced — for everyone.